advertisement
Zou Y 8
Showing records 1 to 8 | Display all abstracts from Zou Y117292 The progress of assessment methods and treatments of neovascular glaucoma secondary to central retinal vein occlusion
Qu S
Frontiers in medicine 2023; 10: 1280776
118115 Ripasudil as a Potential Therapeutic Agent in Treating Secondary Glaucoma in HTLV-1-Uveitis: An In Vitro Analysis
Yang M
International journal of molecular sciences 2024; 25:
117292 The progress of assessment methods and treatments of neovascular glaucoma secondary to central retinal vein occlusion
Qu S
Frontiers in medicine 2023; 10: 1280776
118115 Ripasudil as a Potential Therapeutic Agent in Treating Secondary Glaucoma in HTLV-1-Uveitis: An In Vitro Analysis
Kamoi K
International journal of molecular sciences 2024; 25:
117292 The progress of assessment methods and treatments of neovascular glaucoma secondary to central retinal vein occlusion
Zou Y; Yang L
Frontiers in medicine 2023; 10: 1280776
118115 Ripasudil as a Potential Therapeutic Agent in Treating Secondary Glaucoma in HTLV-1-Uveitis: An In Vitro Analysis
Zong Y; Zhang J
International journal of molecular sciences 2024; 25:
117292 The progress of assessment methods and treatments of neovascular glaucoma secondary to central retinal vein occlusion
Wu H
Frontiers in medicine 2023; 10: 1280776
118115 Ripasudil as a Potential Therapeutic Agent in Treating Secondary Glaucoma in HTLV-1-Uveitis: An In Vitro Analysis
Zou Y; Ohno-Matsui K
International journal of molecular sciences 2024; 25:
